Updates are available Correction dated 2024-09-13

Article History

Accepted: 29 July 2024

First Online: 5 September 2024

Change Date: 13 September 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41572-024-00558-2

Competing interests

: I.E.S. received research funding from the National Health and Medical Research Council Australia, Medical Research Future Fund, Health Research Council New Zealand, Shenzhen Sanming Grant and Einstein Visiting Fellowship; served on scientific advisory boards for BioMarin, Cerecin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Takeda Pharmaceuticals, UCB and Xenon Pharmaceuticals; is a non-executive director of Bellberry Ltd; consulted for Atheneum Partners, Biohaven Pharmaceuticals, Care Beyond Diagnosis, Cerecin, Epilepsy Consortium, Eisai, Longboard Pharmaceuticals, Ovid Therapeutics, UCB and Zynerba Pharmaceuticals; received speaker honoraria from Akumentis Healthcare Ltd, Biocodex, BioMarin, Chiesi, Eisai, GlaxoSmithKline, Liva Nova, Stoke Therapeutics, UCB and Zuellig Pharma, and funding for travel from Biocodex, Biomarin, Eisai, Encoded Therapeutics, GlaxoSmithKline, Stoke Therapeutics and UCB; served as a trial investigator for Anavex Life Sciences, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix and Zynerba; is Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies Limited; is on the journal editorial boards for <i>The Lancet Neurology</i>, <i>Epilepsy Currents</i>, <i>Epileptic Disorders</i>, <i>Neurology</i> and <i>Progress in Epileptic Disorders</i> series; may accrue future revenue on pending patent WO2009/086591 (filed 2008); has a patent for <i>SCN1A</i> testing held by Bionomics Inc and licensed to various diagnostic companies (WO/2006/133508); and has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) (PRRT2) WO/2013/059884. S.Z. received research support from Scottish Chief Scientists Office Epilepsy Research UK, Dravet Syndrome UK, Governmental Digital Health & Care, UCB/Zogenix, GW/Jazz Pharma, Dravet Syndrome Foundation, Biocodex and Stoke Therapeutics; has undertaken clinical trials by GW/Jazz Pharma, Zogenix/UCB Pharma, Stoke Therapeutics, Encoded Therapeutics and Marinus Pharmaceuticals; serves on advisory boards; received consultancy fees personal and paid to institution from UCB Pharma, Biocodex, GRIN Therapeutics and Encoded Therapeutics; is clinical lead for the Scottish Genetic Epilepsy Service, Neurodevelopment Theme Lead Epilepsy Research Institute UK; and serves on the Medical Advisory Board Dravet syndrome UK. H.C.M. received funding from the National Institutes of Health and CURE Epilepsy Foundation; received travel support and speaker honorarium from GeneDx, Inc.; is on the medical genetics advisory board for the Simons Powering Autism Research (SPARK) study; serves as a working group member for the Coalition for Aligning Science; and is a member of the Board of Directors for American Society of Human Genetics and Scientific Advisory Boards for Dravet Syndrome Foundation, SynGAP Research Fund, Coalition to Cure CHD2 and Koolen-de Vries Syndrome Foundation. R.G. declares no competing interests. A.M. received consultancy fees and travel expenses via UCL Consulting from UCB, Biogen, Rocket Pharmaceuticals and Jazz Pharmaceuticals paid into departmental funds; receives research funding from the MRC (MR/T007087/1), GOSH Charity (VS0122) Wellcome Trust TIN Scheme and GOSH NIHR BRC; and is a scientific adviser to Rare Epilepsies Together UK and the KCNT1 Foundation. For A.M. this work is supported by the NIHR GOSH BRC.